Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02432326 · ClinicalTrials.gov registry record · Phase 1
A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
A Phase 1 study of Cancer and Advanced Solid Tumors, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 147
- Enrollment target
- 11
- Study locations
NCT02432326: Completed Phase 1 study of Cancer and Advanced Solid Tumors, sponsored by Sumitomo Pharma America.
NCT02432326 is a Phase 1 study of Cancer and Advanced Solid Tumors that has completed, run by Sumitomo Pharma America. The registered enrollment target is 147 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02432326, a Phase 1 study of Cancer and Advanced Solid Tumors, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 147 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is an open label, multi-center, phase 1 study of BBI608 and BBI503 administered orally in combination to patients with advanced solid tumors. The primary goal is to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination regimen.
Conditions Studied
Interventions
- DRUG BBI608
- DRUG BBI503
Study Locations (11)
Texas
- Texas Oncology - Austin Midtown - Austin
- Texas Oncology - Baylor Charles A. Sammons Cancer Center - Dallas
- Texas Oncology - Fort Worth 12th Ave - Fort Worth
- Texas Oncology, P.A. - San Antonio
- Texas Oncology, P.A. - San Antonio
- Texas Oncology - Tyler - Tyler
Illinois
- University of Chicago Medicine Comprehensive Cancer Center - Chicago
Indiana
- Indiana University Simon Cancer Center - Indianapolis
New York
- Weill Cornell Medical College - New York
Virginia
- Virginia Cancer Specialists, PC - Fairfax
Washington
- Northwest Cancer Specialists, PC - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2015-04 |
| Est. Completion | 2020-04 |
| Phase | Phase 1 |
What the finished NCT02432326 record still lists
NCT02432326 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which BBI608 is the first listed.
NCT02432326 lists 11 locations in 6 states (Texas, Illinois, Indiana).
Frequently Asked Questions
What is clinical trial NCT02432326 about?
NCT02432326 is a clinical study titled "A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors". This is an open label, multi-center, phase 1 study of BBI608 and BBI503 administered orally in combination to patients with advanced solid tumors. The primary goal is to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination regimen.
What is the current status of trial NCT02432326?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2015-04. Estimated completion is 2020-04.
What conditions does trial NCT02432326 study?
This clinical trial studies the following conditions: Cancer, Advanced Solid Tumors.
What interventions are being tested in trial NCT02432326?
The interventions under investigation include: BBI608 (DRUG), BBI503 (DRUG).
Who is sponsoring clinical trial NCT02432326?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02432326 being conducted?
This trial has 11 study locations across Illinois, Indiana, New York, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02432326's enrollment target sits among peer trials
147 271st of 615 higher than 345 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia